Mink Therapeutics Inc INKT.OQ INKT.O is expected to show no change in quarterly revenue when it reports results on August 14 for the period ending June 30 2025
LSEG's mean analyst estimate for Mink Therapeutics Inc is for a loss of 55 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Mink Therapeutics Inc is $39.00, about 68.7% above its last closing price of $12.22
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.60 | -0.61 | -0.70 | Missed | -14.8 |
Dec. 31 2025 | -0.50 | -0.62 | Missed | -24 | |
Sep. 30 2024 | -0.80 | -0.80 | -0.50 | Beat | 37.5 |
Jun. 30 2024 | -0.98 | -1.00 | -0.70 | Beat | 30 |
Mar. 31 2024 | -1.58 | -1.53 | -1.10 | Beat | 28.3 |
Dec. 31 2023 | -1.53 | -1.60 | Missed | -4.3 | |
Sep. 30 2023 | -1.79 | -1.82 | -1.50 | Beat | 17.8 |
Jun. 30 2023 | -1.91 | -1.97 | -1.80 | Beat | 8.9 |
This summary was machine generated August 12 at 13:22 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)